Kathmere Capital Management LLC Makes New Investment in Solana Company $HSDT

Kathmere Capital Management LLC acquired a new stake in Solana Company (NASDAQ:HSDT) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 4,594,960 shares of the company’s stock, valued at approximately $7,949,000. Kathmere Capital Management LLC owned approximately 8.37% of Solana at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in HSDT. Arrington Capital Management LLC acquired a new stake in shares of Solana in the 4th quarter worth about $1,904,000. Rockefeller Capital Management L.P. raised its stake in shares of Solana by 11,764.1% in the fourth quarter. Rockefeller Capital Management L.P. now owns 444,904 shares of the company’s stock worth $1,286,000 after purchasing an additional 441,154 shares during the last quarter. LPL Financial LLC raised its stake in shares of Solana by 120.1% in the fourth quarter. LPL Financial LLC now owns 382,255 shares of the company’s stock worth $1,105,000 after purchasing an additional 208,558 shares during the last quarter. Geode Capital Management LLC bought a new position in shares of Solana in the fourth quarter valued at approximately $1,006,000. Finally, Franchise GP Ltd bought a new position in shares of Solana in the fourth quarter valued at approximately $653,000. 18.63% of the stock is currently owned by institutional investors and hedge funds.

Solana Stock Performance

Shares of Solana stock opened at $1.79 on Monday. The business’s fifty day simple moving average is $1.88 and its 200 day simple moving average is $2.23. The firm has a market capitalization of $104.52 million, a P/E ratio of -0.02 and a beta of 1.03. Solana Company has a 12 month low of $1.19 and a 12 month high of $25.50.

Solana (NASDAQ:HSDT) last posted its quarterly earnings data on Friday, May 15th. The company reported ($1.30) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.96). Solana had a negative return on equity of 67.57% and a negative net margin of 1,427.15%.The business had revenue of $3.62 million during the quarter, compared to analysts’ expectations of $3.40 million. Analysts predict that Solana Company will post -0.09 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on HSDT shares. B. Riley Financial initiated coverage on Solana in a report on Thursday, April 23rd. They set a “buy” rating and a $3.00 price target for the company. Zacks Research raised shares of Solana to a “hold” rating in a report on Monday, April 27th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Solana in a research note on Tuesday, April 21st. Finally, Maxim Group initiated coverage on shares of Solana in a report on Monday, April 6th. They issued a “buy” rating and a $4.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Solana has a consensus rating of “Moderate Buy” and a consensus price target of $3.50.

Solana Company Profile

Helius Medical Technologies, Inc (NASDAQ: HSDT) is a medical technology company focused on developing and commercializing non?invasive neuromodulation platforms designed to enhance neurorehabilitation. Its flagship product, the Portable Neuromodulation Stimulator (PoNS®), delivers mild electrical pulses to the tongue to stimulate neural pathways in conjunction with targeted physical therapy. The device is intended to improve neuroplasticity and support recovery in patients with neurological conditions.

The PoNS system is cleared for use in the United States, Canada and the European Union and is prescribed through specialized rehabilitation clinics.